Key result
Metabolic syndrome in patients with heart failure did not increase all-cause mortality (HR 1.04; 95% CI 0.88-1.23) but increased composite cardiovascular events (HR 1.73; 95% CI 1.23-2.45).
Why the study?
Although metabolic syndrome is associated with incident heart failure, its impact on the prognosis of patients with established heart failure remains controversial.
Does the presence of metabolic syndrome increase the risk of mortality or cardiovascular events in patients with established heart failure?
Meta-Analysis (n=18,590)
Does the presence of metabolic syndrome increase the risk of mortality or cardiovascular events in patients with established heart failure?
In patients with established heart failure, metabolic syndrome is associated with an increased risk of composite cardiovascular events, but not all-cause or cardiovascular mortality.
Metabolic syndrome may raise CV event risk without affecting mortality in HF; supports risk stratification but leaves causal effects open for trials.
Background: The metabolic syndrome (MS) is significantly associated with the risk of incident heart failure (HF). However, there are still great controversies about the impact of MS on the prognosis in patients with established HF. This meta-analysis aimed to ascertain the effect of MS on the prognosis in patients with HF. Methods: We searched multiple electronic databases, including PubMed, Opengrey, EMBASE, and Cochran Library, for potential studies up to February 15, 2021. Observational studies that reported the impact of MS on the prognosis in patients with established HF were included for meta-analysis. Results: Ten studies comprising 18,590 patients with HF were included for meta-analysis. The median follow-up duration of the included studies was 2.4 years. Compared with HF patients without MS, the risk of all-cause mortality and cardiovascular mortality was not increased in HF with MS (HR = 1.04, 95% CI = 0.88–1.23 for all-cause mortality; HR = 1.66, 95% CI = 0.56–4.88 for cardiovascular mortality, respectively). However, there was a significant increase in composited cardiovascular events in the HF patients with MS compared with those without MS (HR = 1.73, 95% CI = 1.23–2.45). Conclusions: In patients with established HF, the presence of MS did not show an association on the risk of all-cause mortality or cardiovascular mortality, while it may increase the risk of composite cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2021) conducted a meta-analysis in Heart Failure (n=18,590). Metabolic syndrome vs. Without metabolic syndrome was evaluated on all-cause mortality (HR 1.04, 95% CI 0.88-1.23). Metabolic syndrome in patients with heart failure did not increase all-cause mortality (HR 1.04; 95% CI 0.88-1.23) but increased composite cardiovascular events (HR 1.73; 95% CI 1.23-2.45).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: